ClinicalTrials.gg
TerminatedNCT01032291Updated May 21, 2013Results posted

A Study to Assess the Efficacy and Safety of Lenalidomide in Combination With Cetuximab in Pre-treated Patients With KRAS Mutant Colorectal Cancer

A Phase 2 interventional study of cetuximab and lenalidomide in Colorectal Cancer, sponsored by Celgene Corporation. Terminated at 17 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-05-21.

Sponsored by Celgene Corporation (part of Bristol-Myers Squibb) · Phase 2, Interventional, and Treatment

Why this study was terminated
A business decision not to continue with Phase 2b based on non-safety observations during proof of concept phase.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
51
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 29 studies in Colorectal Neoplasms by Bristol-Myers Squibb — 4 open to participants now, 9 under way, 3 of them phase 3. Colorectal Neoplasms · Bristol-Myers Squibb.

Enrollment
21st of 27
51 · median 171
Started
2009
with 2 others
Phase 2
5 of 29
none open now
Registered
7th of 29
by date

Among the 29 studies in Colorectal Neoplasms by Bristol-Myers Squibb, this one is the 21st largest by enrollment of the 27 interventional ones that give a count, is one of 3 that started in 2009, is one of 5 in phase 2, and was the 7th registered.

Colorectal Neoplasms

6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

4 of the 29 studies in Colorectal Neoplasms by Bristol-Myers Squibb are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies in Colorectal Neoplasms by Bristol-Myers Squibb, or all of them as a file.
02

Study summary

The purpose of this study is to determine whether lenalidomide in combination with cetuximab is safe and effective in patients with KRAS mutant colorectal cancer.

03

Conditions studied

  • Colorectal Cancer

Keywords

  • Colorectal cancer
  • Revlimid
  • Lenalidomide
  • Cetuximab
  • Erbitux
  • KRAS
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. colorectal adenocarcinoma.
  2. Confirmed K-RAS mutant tumor
  3. Disease progression on oxaliplatin- AND irinotecan-containing regimens, with at least one of these regimens containing bevacizumab.
  4. (ECOG) performance status of ≤ 1.

Exclusion criteria

Exclusion Criteria:

  1. Use of chemotherapy, hormonal therapy, immunotherapy or any other cancer or experimental treatment ≤ 28 days prior to the first day of the first cycle.
  2. Radiotherapy for up to ≥ 30% of the bone marrow.
  3. Surgery ≤ 28 days before day 1 of the first cycle (minimally invasive interventions for diagnostic purposes or disease staging are permitted).
  4. Previous treatment with cetuximab, panitumumab, pomalidomide (CC-4047), lenalidomide or thalidomide.
  5. Untreated, symptomatic (brain imaging not required).
  6. Venous thromboembolism ≤ 6 months before day1 of the first cycle.
  7. Current congestive heart failure (classes II to IV of the ).
  8. Myocardial infarction ≤ 12 months before day1 of the first cycle.
  9. Uncontrolled hypertension.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
51 participants (actual)

Study arms

  • Experimental
    lenalidomide plus cetuximab

    Combination therapy of lenalidomide plus cetuximab

    Drug: cetuximab · Drug: lenalidomide

  • Experimental
    lenalidomide

    Single agent therapy of lenalidomide

    Drug: lenalidomide

Interventions

  • Intravenous infusions of cetuximab (400 mg/m\^2 Cycle 1 Day 1, thereafter 250 mg/m\^2), administered on days 1, 8, 15 and 22 of each 28 day cycle.

    Also known as: Erbitux

  • Daily oral lenalidomide 25mg on days 1 to 28 of each 28 day cycle

    Also known as: Revlimid

06

What researchers measure

Primary outcomes

  1. Participants With Dose Limiting Toxicities (DLTs) During the First Treatment Cycle of the Safety Lead-In Period

    The number of participants with DLTs determines the maximum tolerated dose of the combination therapy used in the Proof of Concept (POC) period: If \<2 of the initial 6 participants experience a DLT, then the POC will start with lenalidomide at 25 mg. If ≥2 of the initial 6 participants experienced a DLT, then 6 more subjects were to be enrolled at 20 mg lenalidomide. If \<2 of the additional 6 subjects experienced a DLT, then the lenalidomide starting dose for the POC was to be 20 mg. If ≥2 of the additional 6 subjects experienced a DLT, then 6 more subjects were to be enrolled at 15 mg lenalidomide. If \<2 of the additional 6 subjects experienced a DLT, then the POC was to start with lenalidomide at 15 mg. If ≥2 of the additional 6 subjects experienced a DLT, the dosing for the study was to be reassessed by Celgene Corporation and the investigators.

    Time frame: Up to Day 28 (Cycle 1)

  2. Percentage of Participants With a Response to Treatment During the Proof of Concept Period

    Tumor response was evaluated every 2 cycles beginning with Cycle 3 Day 1 and at treatment discontinuation. Response and progression were evaluated using the RECIST 1.1 criteria (Eisenhauer, 2009). Treatment response includes both complete response and partial response. * Complete response-disappearance of all lesions * Partial response-30% decrease in the sum of diameters of target lesions from baseline Analysis was not performed due to the early termination of the study.

    Time frame: week 9 up to week 24

Secondary outcomes

  1. Kaplan-Meier Estimates for Progression Free Survival (PFS)

    PFS was calculated as the time from randomization to the earlier of the first documentation of progressive disease (PD), or death on study due to any cause. Analysis was not performed due to the early termination of the study.

    Time frame: up to week 24

  2. Kaplan-Meier Estimates for Duration of Response

    Duration of response was defined as the time from the initial response date to progressive disease (PD) for participants who achieved an objective confirmed complete response (CR) or partial response (PR). Analysis was not performed due to the early termination of the study.

    Time frame: up to week 24

  3. Percentage of Participants With Disease Control

    Known as the Disease Control Rate (DCR), participants with a complete response, partial response or stable disease contribute to the DCR. This analysis was not performed due to the early termination of the study.

    Time frame: up to week 24

  4. Kaplan-Meier Estimates for Overall Survival

    Overall survival was defined as the time between randomization and death. It was intended that participants would be followed for up to 5 years following discontinuation from treatment. Analysis was not performed due to the early termination of the study.

    Time frame: up to 5.5 years

  5. Participants With Treatment-Emergent Adverse Events (TEAE)

    TEAEs are any adverse event occurring or worsening on or after the first treatment of any study drug and within 28 days after the last dose of the last study drug received. Relation to study drug was determined by the investigator. Severity of AE is graded according to National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAE) Version 4.0. Severity is a 5-point scale: 3= severe or medically significant but not life-threatening 4=life-threatening, urgent intervention required 5=death related to AE.

    Time frame: up to week 28

07

Results

Posted May 21, 2013
Limitations and caveats
Enrollment stopped prematurely due to lack of efficacy and failure to achieve the planned response objective.

Participant flow

Safety Lead-in
Participant flow — Safety Lead-in
MilestoneLenalidomide + Cetuximab (Safety Lead-in)Lenalidomide (Proof of Concept)Lenalidomide + Cetuximab (Proof of Concept)
Started800
Completed600
Not completed200
Withdrew: Adverse event100
Withdrew: Death100
Proof of Concept
Participant flow — Proof of Concept
MilestoneLenalidomide + Cetuximab (Safety Lead-in)Lenalidomide (Proof of Concept)Lenalidomide + Cetuximab (Proof of Concept)
Started02221
Intent to treat and safety populations02121
Completed01418
Not completed083
Withdrew: Adverse event051
Withdrew: Death012
Withdrew: Lack of efficacy010
Withdrew: Never received study drug010

Outcome measures

PrimaryParticipants With Dose Limiting Toxicities (DLTs) During the First Treatment Cycle of the Safety Lead-In Period

The number of participants with DLTs determines the maximum tolerated dose of the combination therapy used in the Proof of Concept (POC) period: If \<2 of the initial 6 participants experience a DLT, then the POC will start with lenalidomide at 25 mg. If ≥2 of the initial 6 participants experienced a DLT, then 6 more subjects were to be enrolled at 20 mg lenalidomide. If \<2 of the additional 6 subjects experienced a DLT, then the lenalidomide starting dose for the POC was to be 20 mg. If ≥2 of the additional 6 subjects experienced a DLT, then 6 more subjects were to be enrolled at 15 mg lenalidomide. If \<2 of the additional 6 subjects experienced a DLT, then the POC was to start with lenalidomide at 15 mg. If ≥2 of the additional 6 subjects experienced a DLT, the dosing for the study was to be reassessed by Celgene Corporation and the investigators.

Time frame:
Up to Day 28 (Cycle 1)
Reported as:
Number · participants
Participants With Dose Limiting Toxicities (DLTs) During the First Treatment Cycle of the Safety Lead-In Period
participantsLenalidomide Plus Cetuximab (Safety Lead-in)
Participants With Dose Limiting Toxicities (DLTs) During the First Treatment Cycle of the Safety Lead-In Period1
Post-hocBest Overall Response Assessed by an Independent Review Using Response Evaluation Criteria In Solid Tumors (RECIST 1.1) During the Proof of Concept Period Prior to Early Study Termination

Tumor response was evaluated every 2 cycles beginning with Cycle 3 Day 1 and at treatment discontinuation. Response and progression were evaluated using the RECIST 1.1 criteria (Eisenhauer, 2009). * Complete response-disappearance of all lesions * Partial response-30% decrease in the sum of diameters of target lesions from baseline * Stable disease-neither shrinkage nor increase of lesions. * Progressive Disease-20% increase in the sum of diameters of target lesions from nadir. Participants with evidence of objective tumor response have the response confirmed with repeat assessments performed at the next scheduled scan.

Time frame:
Week 9 up to week 24
Reported as:
Number · participants
Best Overall Response Assessed by an Independent Review Using Response Evaluation Criteria In Solid Tumors (RECIST 1.1) During the Proof of Concept Period Prior to Early Study Termination
participantsLenalidomide (Proof of Concept)Lenalidomide Plus Cetuximab (Proof of Concept)
Complete Response00
Partial Response00
Stable Disease35
Progressive Disease1313
Response Not Evaluable53
SecondaryKaplan-Meier Estimates for Progression Free Survival (PFS)

PFS was calculated as the time from randomization to the earlier of the first documentation of progressive disease (PD), or death on study due to any cause. Analysis was not performed due to the early termination of the study.

Time frame:
up to week 24

No measurements were reported for this outcome.

SecondaryKaplan-Meier Estimates for Duration of Response

Duration of response was defined as the time from the initial response date to progressive disease (PD) for participants who achieved an objective confirmed complete response (CR) or partial response (PR). Analysis was not performed due to the early termination of the study.

Time frame:
up to week 24

No measurements were reported for this outcome.

SecondaryPercentage of Participants With Disease Control

Known as the Disease Control Rate (DCR), participants with a complete response, partial response or stable disease contribute to the DCR. This analysis was not performed due to the early termination of the study.

Time frame:
up to week 24

No measurements were reported for this outcome.

SecondaryKaplan-Meier Estimates for Overall Survival

Overall survival was defined as the time between randomization and death. It was intended that participants would be followed for up to 5 years following discontinuation from treatment. Analysis was not performed due to the early termination of the study.

Time frame:
up to 5.5 years

No measurements were reported for this outcome.

SecondaryParticipants With Treatment-Emergent Adverse Events (TEAE)

TEAEs are any adverse event occurring or worsening on or after the first treatment of any study drug and within 28 days after the last dose of the last study drug received. Relation to study drug was determined by the investigator. Severity of AE is graded according to National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAE) Version 4.0. Severity is a 5-point scale: 3= severe or medically significant but not life-threatening 4=life-threatening, urgent intervention required 5=death related to AE.

Time frame:
up to week 28
Reported as:
Number · participants
Participants With Treatment-Emergent Adverse Events (TEAE)
participantsLenalidomide Plus Cetuximab (Safety Lead-In)Lenalidomide (Proof of Concept)Lenalidomide Plus Cetuximab (Proof of Concept)
>=1 TEAE82021
Serious TEAE599
TEAE leading to discontinuing lenalidomide375
TEAE leading to discontinuing cetuximab3NA6
TEAE leading to reduction/interruption of lenalido269
TEAE leading to reduction/interruption of cetuxima1NA7
TEAE related to lenalidomide5913
TEAE related to cetuximab8NA19
TEAE NCI CTC grade 3 or higher41312
TEAE NCI CTC grade 3+ related to lenalidomide344
TEAE NCI CTC grade 3+ related to cetuximab2NA7
Serious TEAE related to lenalidomide202
Serious TEAE related to cetuximab2NA2
PrimaryPercentage of Participants With a Response to Treatment During the Proof of Concept Period

Tumor response was evaluated every 2 cycles beginning with Cycle 3 Day 1 and at treatment discontinuation. Response and progression were evaluated using the RECIST 1.1 criteria (Eisenhauer, 2009). Treatment response includes both complete response and partial response. * Complete response-disappearance of all lesions * Partial response-30% decrease in the sum of diameters of target lesions from baseline Analysis was not performed due to the early termination of the study.

Time frame:
week 9 up to week 24

No measurements were reported for this outcome.

Adverse events

Collected over up to 28 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Lenalidomide (Proof of Concept)—9/21 (42.9%)16/21 (76.2%)
Lenalidomide + Cetuximab (Safety Lead-in and Proof of Concept)—14/29 (48.3%)29/29 (100%)
Most frequent serious events
Showing 10 of 30
Most frequent serious events
EventLenalidomide (Proof of Concept)Lenalidomide + Cetuximab (Safety Lead-in and Proof of Concept)
General Physical Health DeteriorationGeneral disorders2/213/29
Abdominal painGastrointestinal disorders2/210/29
HyperbilirubinaemiaHepatobiliary disorders0/212/29
DyspnoeaRespiratory, thoracic and mediastinal disorders0/212/29
DiarrhoeaGastrointestinal disorders0/212/29
PyrexiaGeneral disorders1/211/29
ConstipationGastrointestinal disorders1/210/29
Large Intestine PerforationGastrointestinal disorders1/210/29
Rectal ObstructionGastrointestinal disorders1/210/29
AstheniaGeneral disorders1/211/29
Most frequent other events
Showing 10 of 49
Most frequent other events
EventLenalidomide (Proof of Concept)Lenalidomide + Cetuximab (Safety Lead-in and Proof of Concept)
RashSkin and subcutaneous tissue disorders6/2120/29
DiarrhoeaGastrointestinal disorders1/2114/29
FatigueGeneral disorders6/2111/29
NauseaGastrointestinal disorders4/2110/29
Abdominal painGastrointestinal disorders5/219/29
AstheniaGeneral disorders6/219/29
Dry skinSkin and subcutaneous tissue disorders0/218/29
VomitingGastrointestinal disorders2/217/29
AnorexiaMetabolism and nutrition disorders3/217/29
ConstipationGastrointestinal disorders3/216/29

Baseline characteristics

Age, Customized
Age, Customized(participants)Lenalidomide Plus Cetuximab (Safety Lead-In)Lenalidomide (Proof of Concept)Lenalidomide Plus Cetuximab (Proof of Concept)Total
<= 65 years7161841
>65 years1539
Sex: Female, Male
Sex: Female, Male(Participants)Lenalidomide Plus Cetuximab (Safety Lead-In)Lenalidomide (Proof of Concept)Lenalidomide Plus Cetuximab (Proof of Concept)Total
Female49922
Male4121228
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Lenalidomide Plus Cetuximab (Safety Lead-In)Lenalidomide (Proof of Concept)Lenalidomide Plus Cetuximab (Proof of Concept)Total
Caucasian (White)8212049
Other (Not Specified)0011
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Lenalidomide Plus Cetuximab (Safety Lead-In)Lenalidomide (Proof of Concept)Lenalidomide Plus Cetuximab (Proof of Concept)Total
Hispanic or Latino0000
Non-Hispanic or Latino8212150
Eastern Cooperative Oncology Group Performance Status
Eastern Cooperative Oncology Group Performance Status(participants)Lenalidomide Plus Cetuximab (Safety Lead-In)Lenalidomide (Proof of Concept)Lenalidomide Plus Cetuximab (Proof of Concept)Total
06101430
1210719
20101
3-50000
08

Study locations

17 sites
  • Flinders Medical Centre, Dept. of Oncology
    Bedford Park, South Australia, Australia
  • UZ Antwerpen Dept. of Medical Oncology
    Antwerp, Belgium
  • ULB Erasme Service de Gastroenterologie
    Brussels, Belgium
  • Grand hôpital de Charleroi, Oncologie
    Charleroi, Belgium
  • Algemeen Ziekenhuis Maria Middelares
    Gent, Belgium
  • Universitaire Ziekenhuis Gasthuisberg K.U. Leuven Gastroenterologie, Oncologie
    Leuven, Belgium
  • Centre Hospitalier Universitaire Sart Tilman Liège
    Liège, Belgium
  • Klinikum Oldenburg gGmbH Klinik für Innere Medizin II
    Oldenburg, Niedersachsen, Germany
  • Azienda Osperdaliero Universitaria Riuniti Umberto I-GM Lancisi-G. Salesi di Ancona Clinica di Oncologia Medica
    Ancona, Italy
  • Azienda Ospedaliera Universitaria San Martino Unità Operativa Oncologia Medica
    Genova, Italy
  • Azienda Ospedaliera Niguarda Ca' Grande, Oncologia Medica Falck
    Milano, Italy
  • Hospital Vall D'Hebron Servicio de Oncología. Unidad de ensayos clínicos
    Barcelona, Spain
  • Hospital Universitario Marques de Valdecilla Servicio de Oncología
    Santander, Spain
  • Hospital Clinico Universitario de Valencia Servicio de Oncologia
    Valencia, Spain
  • Östra Sjukhuset Kirurgkliniken
    Gothenburg, Sweden
  • Karolinska University Hospital, Solna, Karolinska Institutet Dept of Oncology
    Stockholm, Sweden
  • Akademiska Sjukhuset Onkologkliniken
    Uppsala, Sweden
09

References and documents

Publications

  • Gandhi AK, Shi T, Li M, Jungnelius U, Romano A, Tabernero J, Siena S, Schafer PH, Chopra R. Immunomodulatory effects in a phase II study of lenalidomide combined with cetuximab in refractory KRAS-mutant metastatic colorectal cancer patients. PLoS One. 2013 Nov 11;8(11):e80437. doi: 10.1371/journal.pone.0080437. eCollection 2013. PubMed 24244687 ↗
  • Siena S, Van Cutsem E, Li M, Jungnelius U, Romano A, Beck R, Bencardino K, Elez ME, Prenen H, Sanchis M, Sartore-Bianchi A, Tejpar S, Gandhi A, Shi T, Tabernero J. Phase II open-label study to assess efficacy and safety of lenalidomide in combination with cetuximab in KRAS-mutant metastatic colorectal cancer. PLoS One. 2013 Nov 11;8(11):e62264. doi: 10.1371/journal.pone.0062264. eCollection 2013. PubMed 24244261 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2009, a primary completion of Jan 2011 and a completion of Jan 2011. It does not say whether these dates are actual or estimated.

Results were first posted in May 2013, 2 years 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 14, 2009
First posted
Dec 15, 2009
Start
Dec 2009
Primary completionActual
Jan 2011
CompletionActual
Jan 2011
Results first posted
May 21, 2013
Last update
May 21, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 21, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01032291
Responsible party
Sponsor
First posted
Dec 15, 2009
Start date
Dec 2009
Primary completion
Jan 2011
Completion
Jan 2011
Results posted
May 21, 2013
Last update
May 21, 2013

Study contacts

Eric Van Cutsem, M.D., Ph,D
principal investigator · Universitaire Ziekenhuis Gasthuisberg K.U. Leuven, Belgium
Josep Tabernero, M.D.
principal investigator · Hospital Vall d´Hebrón, Servicio de Oncología, Barcelona. Spain

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lenalidomide

Start the discussion